Mitochondrial very-long-chain acyl-coenzyme A dehydrogenase (VLCAD) was purified from human liver. The molecular masses of the native enzyme and the subunit were estimated to be 154 and 70 kD, respectively. The enzyme was found to catalyze the major part of mitochondrial palmitoylcoenzyme A dehydrogenation in liver, heart, skeletal muscle, and skin fibroblasts (89-97, 86-99, 96-99, and 78-87%, respectively).
Introduction
Inborn errors of fatty acid metabolism are a group of diseases affecting infants and children. More than 13 separate inherited disorders of mitochondrial fatty acid /3-oxidation have been described in humans, and the characterization of these disorders at the clinical and biochemical levels has progressed (1) (2) (3) (4) .
Within the group of acyl-coenzyme A (CoA) dehydrogenases that catalyze the first reaction in the mitochondrial /3-oxidation of straight-chain fatty acid of various chain lengths, deficiencies of three enzymes have been reported (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . Among these defects, medium-chain acyl-CoA dehydrogenase (MCAD)' deficiency is relatively common. MCAD deficiency often remains undetected and asymptomatic for months or years until a metabolic crisis is induced by infection or fasting. In contrast to MCAD deficiency, other defects, such as short-chain acyl-CoA dehydrogenase and long-chain acyl-CoA dehydrogenase (LCAD) deficiencies, are rare. The detailed clinical descriptions of these defects are quite variable, and many patients die before 1 yr of age (12) (13) (14) (15) (16) (17) (18) (19) (20) .
Recently, a novel fatty acyl-CoA dehydrogenase, "verylong-chain acyl-CoA dehydrogenase (VLCAD)," has been purified from rat liver mitochondria and characterized in our laboratory (21) . VLCAD is unique among acyl-CoA dehydrogenases in its size, structure, and intramitochondrial distribution. While the other acyl-CoA dehydrogenases are homotetramers of a 43-45-kD subunit, VLCAD is a dimer of a 70-kD subunit, each containing a 29-kD extra polypeptide compared with the subunits of other dehydrogenases. VLCAD also differs from three other acyl-CoA dehydrogenases in that it is loosely bound to the mitochondrial inner membrane and requires detergent for solubilization, while three others are readily extractable into the soluble fraction without detergent, indicating that they are localized in the mitochondrial matrix. It is noteworthy that, catalytically, VLCAD has a 10 times higher specific activity toward palmitoyl-CoA than that of LCAD. It was considered previously that LCAD was mainly responsible for the dehydrogenation of palmitoyl-CoA. In addition, VLCAD is active toward CoA esters of longer chain substrates such as arachidoylCoA, behenoyl-CoA, and lignoceroyl-CoA, but it is not active toward those of medium-and short-chain substrates (21) .
To search for patients with VLCAD deficiency, we previously determined palmitoyl-CoA dehydrogenase activity in skin fibroblasts from seven patients who were suspected of having a disorder of mitochondrial 3-oxidation. Among them, we found abnormally low VLCAD activity in two patients (22) . At the same time, skin fibroblasts from these two patients were found to have trace amounts of VLCAD protein in immunoblot analysis. Furthermore, three additional VLCAD patients were identified among those who were diagnosed previously as having LCAD deficiency (23) .
In this paper, we describe the purification and characterization of VLCAD from normal human liver and report in detail our biochemical and immunochemical investigations of fibroblasts from these five VLCAD-deficient patients and two additional patients who were subsequently identified.
Methods

Case history
The case histories were partially described in the previous reports (12, 13, 22, (24) (25) (26) . We describe them as follows. Patient 1 was first noted to be hypotonic and developmentally delayed at age 2 mo. He then presented acutely at the age of 3 mo with hypoketotic hypoglycemia, hepatocellular dysfunction, and cardiomyopathy. Initial laboratory examinations showed abnormally increased blood levels of bilirubin, GOT, GPT, uric acid, and lactic acid, as well as a low level of total serum carnitine and increased levels of long-chain acylcarnitine esters. Urinary organic acid analysis showed a medium-chain 3-hydroxydicarboxylic aciduria without increased levels of medium-chain acylglycines. Despite some clinical improvement of the patient after restriction to a high carbohydrate, low-fat diet, the cardiac disease worsened and he died after 3 wk of hospitalization. At autopsy, severe hepatocellular injury and lipid storage in many tissues were found. Patient 2 presented at the age of 4 mo with nystagmus, hepatomegaly, poor head control, generalized hypotonia, myoclonic jerks, hypoglycemia, and cardiomyopathy. Laboratory examinations revealed mild metabolic acidosis, abnormal liver function tests, and hyperammonemia. Urinary organic acid analysis revealed lactic, glutaric, adipic, octanedioic, decanedioic, and palmitic acid excretion. Subsequently, the muscular hypotonia worsened and she developed significant cardiomyopathy and hypoglycemia. She died on day 19 of hospitalization after cardiac transplantation. Microscopic examination of autopsy tissues revealed severe macrovesicular lipid storage in heart, liver, kidneys, and skeletal muscle. Patients 3, 4, and 5 were initially reported as having LCAD deficiency (12, 13, 25, 26) , but later, were shown to be deficient in VLCAD, rather than in LCAD, using immunoblot analysis (23) . Patient 6 was reported previously to have LCAD deficiency (12, 13) , but has been found to be deficient in VLCAD in this study. Patient 
Purification of human VLCAD
All procedures except the heat step were carried out at 4°C.
Step 1: extraction. Frozen normal human liver sample (100 g) obtained at autopsy was homogenized with 400 ml of 10 mM K2HPO4 containing 5 mM 2-mercaptoethanol, 1 mM benzamidine, and 0.5 mM phenylmethylsulfonyl fluoride in a blender. The homogenate was centrifuged at 1,000 g for 10 min, and the precipitate was discarded. The supernatant was centrifuged at 100,000 g for 60 min. The pellet was homogenized with 400 ml of 10 mM potassium phosphate, pH 7.5, containing 1% (wt/vol) sodium cholate, 0.5 M NaCl, and a mixture A composed of 0.1% (wt/vol) hexamethylphosphoric triamide, 2 mM 2-mercaptoethanol, 1 mM EDTA, and 10
IkM flavine adenine dinucleotide (FAD). The suspension was centrifuged at 100,000 g for 60 min.
Step 2: heat and ammonium sulfate fractionation. The extract was heated (52-530C) and then fractionated with ammonium sulfate as described previously (21) .
Step 3: phosphocellulose column chromatography. The desalted enzyme solution was applied to a phosphocellulose column ( 1.5 x 12 cm) equilibrated with 10 mM potassium phosphate, pH 7.5, containing 0.2% (wt/vol) Tween 20 and mixture A. The column was washed with the same buffer, and the elution was performed with a linear gradient of 10-200 mM potassium phosphate, pH 7.5, containing 0.2% (wt/vol) Tween 20 and mixture A, in a total volume of 120 ml.
Step 4: DEAE-cellulose column chromatography. Active fractions were pooled and diluted threefold with 0.2% (wt/vol) Tween 20 containing mixture A and applied to a DEAE-cellulose column (1.5 X 8 cm) equilibrated with 30 mM potassium phosphate, pH 7.5, containing 0.2% (wt/vol) Tween 20 and mixture A. The column was washed with the same buffer, and the elution was performed with a linear gradient of 30-300 mM potassium phosphate, pH 7.5, containing 0.2% (wt/ vol) Tween 20 and mixture A, in a total volume of 80 ml.
Step Western blot analysis Sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and Western blotting were performed by the described method (27), using 10% acrylamide, 0.3% bisacrylamide-containing SDS-polyacrylamide gels. Nitrocellulose sheet was incubated with phosphate-buffered saline containing anti-human VLCAD antibody. Protein detection was achieved using alkaline phosphatase-conjugated goat anti-rabbit IgG antibody (KPL Laboratories, Gaithersburg, MD) and nitro-blue-tetrazolium/5-bromo-4-chloro-3-indolyl phosphate substrate kit (Pierce, Rockford, IL).
Pulse-Chase experiment
Fibroblasts were grown in a 28-cm2 dish for pulse-chase experiments. The cells were washed twice with methionine-free modified Eagle's medium containing 5% (vol/vol) dialyzed fetal calf serum and then incubated for 1 h in the same medium at 37°C. The medium was replaced with 1 ml of the same medium containing 120 pCi of [35S]methionine (New England Nuclear, Wilmington, DE). After a 1.5-h incubation, the labeling medium was changed to the standard medium, and the preparation was chased for 6, 24, or 48 h, respectively. The labeled cells were washed twice with phosphate-buffered saline and harvested in 500 ILI of 10 mM Tris-Cl (pH 7.5)/2 mM EDTA/0.1% SDS/0.1% Triton X-100/0.1% bovine serum albumin/10 mM methionine/0.02% sodium azide/protease inhibitors. The suspension was sonicated and centrifuged at 10,000 g for 10 min, and the supernatant was preserved for immunoprecipitation. 35S (28, 29) .
Other methods
Protein concentration was determined using a BCAt9 protein determination kit (Pierce). Acyl-CoA dehydrogenation activities in liver, heart, and skeletal muscle were measured by the method as described (30) . The activities in fibroblasts were measured by the method coupling with ferricenium ion (31) . All samples were treated with Triton X-100 as described (22) .
Results
Purification of human VLCAD. The purification of human liver mitochondrial VLCAD is summarized in Table II . The yield was high, even though whole liver homogenate was used as the starting material. The homogenate obtained from 100 g of human liver was used.
The results of SDS-polyacrylamide gel electrophoresis of the final preparation are shown in Fig. 1 . Purified human VLCAD migrated slightly faster than rat VLCAD (21) . The molecular mass of the subunit of human VLCAD was estimated to be 70 kD. The native molecular mass of human VLCAD was estimated by gel chromatography using Ultrogel AcA 34 and Sephadex G-150 (TOSO, Tokyo, Japan). The enzyme activity peak corresponded to a molecular mass of 154 kD (data not shown). Thus, human VLCAD is probably a homodimer, as is the case for rat VLCAD (21) .
The final preparation was used for FAD determination. The protein was deproteinized with trichloroacetic acid, and the supernatant was neutralized with K2HPO4. The absorbance of this solution at 450 nm was measured. Based on the molar extinction coefficient of FAD at this wavelength ( 1 1,300 M -' cm-') ( (33) . The contribution of VLCAD to the reaction in normal human liver and heart was measured using anti-human VLCAD antibody. As shown in Table III , the major part (89-97% in liver, 86-99% in heart) of the mitochondrial palmitoyl-CoA dehydrogenase activity was catalyzed by VLCAD. Contribution of VLCAD to the reaction in normal human skeletal muscle was also examined. The activities without and with anti-human VLCAD antibody were 1.36±0.12 and 0.04±0.03 mU/mg protein (n = 3), respectively. These data indicate that the major part (> 97%) of the activity in skeletal muscle was catalyzed by VLCAD as well as in liver and heart, and VLCAD content in skeletal muscle was much lower than that in liver and heart, as described in rat (29) . On the other hand, the major part (82-90% in liver, 87-90% in heart) of the octanoyl-CoA dehydrogenation activity by the enzymes was catalyzed by MCAD. Palmitoyl-CoA dehydrogenation activities in human livers in the absence and presence of anti-rat LCAD antibody were 5.83±0.69 and 5.66±0.91 mU/mg protein (n = 5), respectively. OctanoylCoA dehydrogenation activities were 2.88±0.38 and 2.42±0.44 mU/mg protein (n = 5), respectively. Contributions of LCAD to the palmitoyl-CoA and octanoyl-CoA dehydrogenation activities in liver were then < 3 and 16%, respectively. These and other previous data (34) suggest that the role of LCAD is limited the oxidation of CI0-C14 acyl-CoAs. To further study the role of VLCAD in palmitoyl-CoA oxidation, five human liver samples and three heart samples described in Table III were examined by immunoblot analysis. As shown in Fig. 2 A, a clear single band of VLCAD was detected in each of the livers. Specific activity ranged from 4.9 to 6.0 unit/mg, the values similar to that (6.14 unit/mg) of purified human VLCAD (Table II) . In Fig. 2 B, a clear band of VLCAD was also found in each of the hearts. Specific activity ranged from 6.2 to 8.3 unit/mg, values somewhat higher than that (6.14 unit/mg) of purified human VLCAD. These data support the notion that VLCAD is the major catalyst for mitochondrial palmitoyl-CoA dehydrogenation both in liver and heart. Fig. 2 (Fig. 3) . Several bands of varying intensities, migrating at higher rates than the VLCAD protein, were detected in all of the seven samples (patients 1-7). These bands may be intermediates on the degradation pathway in the fibroblasts concerning the synthesized VLCAD, because the bands had specific cross-reactivity against anti-human VLCAD antibody. Similar bands were observed in rat hepatoma cells expressing rat VLCAD (29) . In each of the cells from the 19 other candidates, the amount of VLCAD protein that was similar to those found in the control fibroblasts was detected (data not shown). We also examined other mitochondrial proteins and a peroxisomal protein using immunoblot analysis. (Fig. 4 A) . In contrast, a very faint fluorographic band was observed only at the 1.5-h pulse in patient l's fibroblasts (Fig. 4 A) (Fig. 4 A) . The band seemed to migrate at a slightly higher rate than the band in the control fibroblasts. No band was also observed at 6-, 24-, and 48-h chases in patient 2's fibroblasts after prolonged ( 168 h) fluorographic exposure. Since no band was detected at 6-, 24-, and 48-h chases in the fibroblasts from each of patients 3-7 even after the longer exposure (168 h), only the data concerning 1.5-h pulse and competition experiment of 1.5-h pulse are summarized in Fig. 4 VLCAD-dependentpalmitoyl-CoA dehydrogenation activity in patients 'fibroblasts. To test whether the patients' fibroblasts exhibited VLCAD activity or not, palmitoyl-CoA dehydrogenation activity in patients' fibroblasts was measured in the presence and absence of anti-human VLCAD antibody. As shown in Table IV , the normal palmitoyl-CoA dehydrogenation activities (8.87-9.54 mU/mg protein) found in the control fibroblasts were strongly reduced in the presence of anti-human VLCAD antibody. The data indicate that > 80% of the palmitoyl-CoA dehydrogenation in the control fibroblasts was catalyzed by VLCAD. The residual palmitoyl-CoA dehydrogenation activity (1.03-3.61 mU/mg protein) found in the seven patients' fibroblasts was hardly inhibited in the presence of anti-human VLCAD antibody, clearly indicating the absence of activity due to VLCAD in the patients' fibroblasts. Normal octanoyl-CoA dehydrogenation activities were found both in the control and the patients' fibroblasts (Table IV), indicating that the patients' fibroblasts had normal levels of MCAD. Since normal palmitoyl-CoA dehydrogenation activities (7.64-10.31 mU/mg protein) were detected in the fibroblasts from the other 19 candidates, the possibility for a type of VLCAD deficiency having a normal level of the inactive variant VLCAD protein was excluded.
Long-chainfatty acid oxidation activity infibroblasts. Table  V shows that VLCAD catalyzes the major part of mitochondrial palmitoyl-CoA dehydrogenation in liver, heart, skeletal muscle, and skin fibroblasts. The data presented in this paper, together with those previously published (21, 29) , suggest that human VLCAD is a rate-limiting enyzme in the long-chain fatty acid /3-oxidation system and that VLCAD plays a central role in the catabolism of long-chain fatty acids in human tissues. This is in contrast to the previous prevailing view that such a central, rate-limiting role in the long-chain fatty acid /3-oxidation was played by LCAD. In view of the new data on VLCAD and with reconsideration of the substrate specificity of rat LCAD (34, 36) , it is likely that the role of LCAD is probably limited to the oxidation of C10-Cl4 acyl-CoAs. Values are means+SD (n = 3). * The value (-POCA) minus that of (+POCA). * Ratio of patient activity versus mean of four control activities.
We found that the antibody raised against the purified human VLCAD was superior to that raised against purified rat VLCAD for the study of normal and variant VLCAD in human tissues.
We recognized that, with the use of anti-human VLCAD antibody, an intense VLCAD band was detectable in the immunoblot analysis of human fibroblasts extracts, while no significant interfering band was observed. This is in contrast to the previous experience using antibody raised against rat VLCAD protein.
With the use of anti-rat VLCAD antibody, the intensity of the cross-reactivity against the human VLCAD protein was only 25% of that observed with anti-human VLCAD antibody (Aoyama, T., and T. Hashimoto, unpublished observations). Furthermore, a strong nonspecific band near the VLCAD protein was observed when anti-rat VLCAD antibody was used (Aoyama, T., and T. Hashimoto, unpublished observations). Therefore, we consider that it is important to use anti-human VLCAD antibody in the analysis of human variant VLCAD.
The size of the VLCAD protein detected in human liver, heart, and skin fibroblast, respectively, was identical to that of the purified VLCAD protein. This is consistent with the previous data that the size and content of both the VLCAD protein and mRNA in various rat organs were identical, suggesting the existence of a single species of VLCAD in various organs (29) .
In each of liver and heart samples, palmitoyl-CoA dehydrogenation activity measured by the method using 2,6-dichlorophenolindophenol and phenazine methosulfate (30) was roughly proportional to the amount of the VLCAD protein detected in immunoblot analysis (Table Ill, Fig. 2 ). In the study of fibroblasts, the assay method using 2,6-dichlorophenolindophenol and phenazine methosulfate was subject to interference and was unreliable. Therefore, the ferricenium method (31 ) was applied. Since the latter method is sensitive and reproducible, without being subject to interference, it is a useful and reliable method for the study of long-chain acyl-CoA dehydrogenase deficiencies using fibroblasts and lymphocytes.
The fibroblasts from patients 1-7 hardly contained the VLCAD protein (Fig. 3) . These cells had a markedly reduced Very-Long-Chain Acyl-Coenzyme A Dehydrogenase Deficiency 2471 ability to synthesize the VLCAD protein (Fig. 4) and exhibited a low dehydrogenation activity toward palmitoyl-CoA (Table  IV) . These data indicate that all seven patients had VLCAD deficiency. Mitochondrial long-chain fatty acid oxidation activities in the seven VLCAD-deficient fibroblasts were only 7-31% of the mean of the control fibroblasts (Table V) . In patients with VLCAD deficiency, the impaired ability of the cells to oxidize fatty acids is probably responsible for the common symptoms, such as hypoketotic hypoglycemia, increased levels of longchain acylcarnitine esters, low levels of total serum carnitine, organic aciduria, hyperammonemia, hepatocellular dysfunction, and severe lipid storage in organs.
The results obtained in the immunoblot analysis (Fig. 3 ) and pulse-chase experiments (Fig. 4) suggest that the nature of the variant VLCAD protein in the seven patients is heterogenous. Since it is difficult to further define the nature of the deficiency at the protein level, mutation analysis at the DNA level needs to be carried out for better understanding of the cause of deficiency.
In this study, we analyzed human skin fibroblasts using antihuman VLCAD antibody and characterized VLCAD deficiency in detail. Bertand et al. (37) reported another method to identify VLCAD deficiency. They separated VLCAD and LCAD by differential solubilization of proteins in fibroblasts. We investigated this method by immunoblotting using anti-human VLCAD antibody. About 20 and 80% of VLCAD protein were distributed to the supernatant and membrane fractions, respectively, suggesting that it is possible to identify VLCAD deficiency by measuring palmitoyl-CoA dehydrogenation activity in membrane fraction; in contrast, it may be hard to identify isolated LCAD deficiency by measuring this activity in supernatant fraction containing significant amounts of contaminating VLCAD.
The clinical survey of the eight patients indicates that VLCAD deficiency appears to be widely distributed geographically. The sources of patients included in this study are as follows: six from North America (patients 1-6) and one each from Asia (patient 7) and Europe (37) . The ethnic origins of the patients are seven Caucasians (patients 1-6) (37) and one Asian (patient 7).
The clinical features of VLCAD deficiency include early onset (within 4 mo after birth), high mortality (75% within 2 mo after onset), and high frequencies of having liver dysfunction and cardiac disease (100%, respectively). Among these, cardiac disease seems to be particularly important, because at least four patients presented with hypertrophic cardiomyopathy. This frequency (> 57%) was rather high among diseases involving mitochondrial fatty acid oxidation and carnitine transport (38) (39) (40) (41) (42) . The impaired long-chain fatty acid 13-oxidation activity in the patients would cause the shortage of energy owing to the inadequate muscle fat utilization and the deficient production of ketone bodies, normally the preferential fuel for myocardium and skeletal muscle. It would also cause accumulation of long-chain triglycerides and long-chain acylcarnitines, which may be toxic to cardiac muscle (43) . These unfavorable factors may relate to the occurrence of cardiac diseases such as arrhythmia, cardiomegaly, and cardiomyopathy, and muscular disorders such as episodic muscle pain, rhabdomyolysis, and progressive muscular weakness.
